Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Accounts Payables: 2014-2024

Historic Accounts Payables for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $9.8 million.

  • Viking Therapeutics' Accounts Payables rose 1637.40% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 1637.40%. This contributed to the annual value of $9.8 million for FY2024, which is 30.63% up from last year.
  • Viking Therapeutics' Accounts Payables amounted to $9.8 million in FY2024, which was up 30.63% from $7.5 million recorded in FY2023.
  • In the past 5 years, Viking Therapeutics' Accounts Payables registered a high of $9.8 million during FY2024, and its lowest value of $1.4 million during FY2021.
  • Over the past 3 years, Viking Therapeutics' median Accounts Payables value was $8.5 million (recorded in 2022), while the average stood at $8.6 million.
  • Per our database at Business Quant, Viking Therapeutics' Accounts Payables tumbled by 63.79% in 2021 and then surged by 490.65% in 2022.
  • Over the past 5 years, Viking Therapeutics' Accounts Payables (Yearly) stood at $4.0 million in 2020, then crashed by 63.79% to $1.4 million in 2021, then skyrocketed by 490.65% to $8.5 million in 2022, then dropped by 11.92% to $7.5 million in 2023, then soared by 30.63% to $9.8 million in 2024.